Histotripsy: Innovations in Liver Tumor Management

Overview

This lecture by Dr. Joseph Herman, Medical Director at HistoSonics and nationally recognized radiation oncologist, presents histotripsy as an emerging non-invasive technology for liver tumor management, exploring its mechanism of action, clinical application, and differentiation from existing therapies.

Key Clinical Topics

• Mechanism of action of histotripsy and the Edison platform
• Differentiation between histotripsy and HIFU (High-Intensity Focused Ultrasound)
• Tissue selectivity and preservation of vascular and biliary structures
• Post-treatment involution and imaging response
• The #HOPE4Liver feasibility study and FDA clearance for liver tumor treatment
• Potential expansion to pancreatic and other gastrointestinal cancers

Key Learning Points

• Acoustic cavitation: The core mechanism of histotripsy; high-amplitude, high-pressure ultrasound waves coalesce at a single point in space to mechanically destroy tumor cells immediately and precisely
• Edison platform: A mobile, non-shielded system utilizing piezoelectric elements, a degassed water coupler, and a patented membrane to deliver treatment; does not require a shielded operating room
• Planning Treatment Volume (PTV): Physician-defined treatment contour analogous to radiation therapy planning; treatment effect is confined exclusively to the designated zone with no meaningful penumbra
• No thermal effect: Unlike HIFU, histotripsy is a mechanical rather than thermal process; the goal is to minimize heat generation; the destructive effect is strictly localized to the bubble cloud
• Structural tissue preservation: Collagen-rich structures such as bile ducts and blood vessels resist the bubble cloud, enabling treatment of centrally located tumors without vascular or biliary injury — a key advantage over other liver-directed therapies
• Involution: Post-treatment, the ablated zone undergoes progressive shrinkage over months as the body clears destroyed tissue, resulting in a smaller residual scar compared to SBRT or Y90
• Repeat treatment feasibility: Patients have undergone treatment 2–3 times in the same area without observed increased adverse effects from overlapping treatments
• Real-time visualization: The bubble cloud is directly visible on ultrasound during treatment, providing immediate procedural confirmation not available with radiation-based approaches
• Imaging interpretation caveat: Retained vessels post-treatment may mimic residual enhancement on imaging; longer follow-up is required to distinguish from true recurrence, as demonstrated in early #HOPE4Liver cases

Clinical Data & Study Results

• #HOPE4Liver study: Feasibility study that provided the clinical foundation for FDA clearance of histotripsy for liver tumor treatment; early imaging misclassification of retained vessels as recurrence was subsequently clarified with extended follow-up

Practical Takeaways

• Consider histotripsy as an additional tool for patients with liver tumors who are ineligible for surgery, SBRT, or other ablative therapies due to anatomical or medical limitations
• Histotripsy can be deployed in standard operating rooms without radiation shielding, increasing institutional accessibility
• When interpreting post-histotripsy imaging, account for retained vascular structures that may appear as enhancement; correlate with clinical trajectory before diagnosing recurrence
• Bile duct and blood vessel proximity should not automatically exclude patients from histotripsy, given demonstrated structural preservation
• Repeat histotripsy in previously treated areas appears feasible and may benefit patients with recurrent or oligoprogressive disease
• Monitor ongoing trials for expansion of histotripsy indications to pancreatic cancer and other gastrointestinal malignancies